Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall

Solara Active Pharma to conduct internal probe on Nizatidine API amid Mylan recall "We understand from Mylan NV#39;s press release dated January 8, 2020, that Mylan Pharmaceuticals has initiated a voluntary recall of three lots of Nizatidine Capsules, USP (150 mg and 300 mg strengths) due to detected trace amounts of impurity...," Solara Active Pharma Sciences in a filing to BSE.

No comments:

Post a Comment